Kodiak Sciences Inc. (NASDAQ: KOD) had its "neutral" rating re-affirmed by analysts at HC Wainwright. They now have a $3.00 price target on the stock.
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results [Yahoo! Finance]
Kodiak Sciences Announces Recent Business Highlights and Fourth Quarter and Full Year 2024 Financial Results
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy [Yahoo! Finance]
Kodiak Sciences Completes Enrollment in Second Registrational Trial of Tarcocimab in Patients with Diabetic Retinopathy